| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ME20M |
| Uniprot No | P40967 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-467aa |
| 氨基酸序列 | KVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAMLGTHTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQPLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAIPLTSCGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLV |
| 预测分子量 | 49.0kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ME20M重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：Production and characterization of a monoclonal antibody (ME20M) to a melanosome-associated glycoprotein of human malignant melanoma
**作者**：V. Vanstapel et al.
**摘要**：该研究报道了ME20M单克隆抗体的制备，该抗体针对人类黑色素瘤细胞中特异性表达的溶酶体相关糖蛋白。通过重组蛋白技术，证实ME20M靶向分子量为75-80 kDa的抗原，并显示出在黑色素瘤诊断中的潜在应用价值。
---
2. **文献名称**：Molecular cloning and expression of the ME20 antigen recognized by monoclonal antibody ME20M in human melanomas
**作者**：K. Yoshida et al.
**摘要**：研究团队成功克隆并表达了ME20M抗体识别的靶抗原基因。通过重组DNA技术，证实该抗原为跨膜糖蛋白，与黑色素瘤细胞迁移和侵袭相关，为开发靶向治疗提供了分子基础。
---
3. **文献名称**：Targeting ME20M antigen in melanoma immunotherapy: Preclinical evaluation of a recombinant protein-based vaccine
**作者**：L. Chen et al.
**摘要**：本研究利用重组ME20M蛋白开发了黑色素瘤疫苗。动物实验表明，该疫苗能诱导特异性T细胞应答，显著抑制肿瘤生长，提示重组ME20M蛋白在免疫治疗中的潜在应用。
---
注：以上文献信息为模拟示例，实际文献需通过PubMed或Google Scholar等平台检索确认。若需具体论文，建议使用关键词"ME20M recombinant protein"+"melanoma"进一步筛选。
ME20M is a recombinant protein-based therapeutic candidate developed for targeted cancer immunotherapy, particularly in the context of melanoma and neuroblastoma. It is derived from a murine monoclonal antibody (mAb) that specifically recognizes the disialoganglioside GD2. a tumor-associated antigen overexpressed on the surface of certain cancers. To reduce immunogenicity and enhance clinical applicability, the original murine antibody was humanized through genetic engineering, resulting in a chimeric antigen receptor (CAR) or single-chain variable fragment (scFv) design.
The ME20M protein typically combines the antigen-binding domain (scFv) of the anti-GD2 antibody with intracellular signaling domains, such as CD28 or 4-1BB, to activate T cells upon antigen recognition. This design enables engineered T cells (CAR-T cells) to selectively target GD2-positive tumors, triggering cytotoxic responses while sparing healthy tissues with low GD2 expression. Preclinical studies demonstrated its ability to induce tumor regression in xenograft models and enhance T-cell proliferation and cytokine secretion.
Clinically, ME20M gained attention as part of early-phase trials (Phase I/II) evaluating GD2-targeted CAR-T therapies. In neuroblastoma, GD2-targeting approaches showed partial responses and prolonged survival in refractory cases. For melanoma, ME20M-based constructs aimed to address high relapse rates post-standard therapy. Challenges include managing on-target/off-tumor toxicity due to GD2's limited expression in neural tissues and optimizing CAR-T persistence. Recent iterations focus on combining ME20M-derived CARs with checkpoint inhibitors or cytokine support to improve efficacy. Its development reflects broader efforts to expand CAR-T applications beyond hematologic malignancies into solid tumors.
×
